Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Earnings Results, Beats Expectations By $0.11 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) announced its quarterly earnings results on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11, Zacks reports. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%.

Enanta Pharmaceuticals Trading Up 14.1 %

Shares of NASDAQ:ENTA opened at $5.59 on Wednesday. The company has a market capitalization of $119.23 million, a PE ratio of -1.02 and a beta of 0.54. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The firm has a 50 day simple moving average of $5.87 and a 200-day simple moving average of $9.61.

Insider Activity

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 13.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ENTA. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday. Robert W. Baird decreased their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. Finally, StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.